[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-prostate-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-prostate-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,72,103,126,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100560264","phase-1-stereotactic-body-radiotherapy-and-177lutetium-psma-in-locally-advanced-prostate-cancer-100560264",false,"NCT06574880","STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I\u002FII Trial","STARLiT","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* ECOG performance status ≤ 1\n* Histologic confirmation of prostate adenocarcinoma of the prostate\n* PSMA avid disease on PSMA PET\u002FCT, where the tumor in the prostate has SUVmax ≥ 10.\n\n  * PSMA PET\u002FCT must be obtained within 4 months.\n* Need ≥ 1 criteria:\n\n  * Node positive disease on PSMA PET\u002FCT or conventional imaging, as defined by having any of the following:\n\n    * Pelvic nodal disease (cN1) as defined by LN stations that commence at the bifurcation of the common iliac vessels\n    * Regional nodal disease (M1a) as defined by LN stations that commence at the bifurcation of the aorta and bifurcation of the proximal inferior vena cava to the common iliac veins.\n  * In the absence of nodal metastasis, must have ≥ 2 of the following\n\n    * i. cT3a or cT3b by conventional imaging (MRI) or PSMA PET\u002FCT\n    * ii. Grade group ≥ 4\n    * iii. PSA ≥ 40 ng\u002FmL\n* Adequate organ and marrow function to receive treatment:\n\n  * Hemoglobin \\> 10 g\u002FdL\n  * White blood cell (WBC) \\> 3000 \u002F mL\n  * Absolute neutrophil count ≥ 1,500 \u002F mcL\n  * Platelets ≥ 100,000 \u002F mcL\n  * Creatinine ≤ 1.5x ULN\n  * Estimated glomerular filtration rate (eGFR)\\* \\> 50 mL\u002Fmin\n  * Total bilirubin\\*\\* \\\u003C 2× ULN\n  * Albumin \\> 3 g\u002FdL\n  * Aspartate aminotransferase (AST) \\\u003C 3× ULN\n\n    * \\*based upon Chronic Kidney Disease- Epidemiology Collaboration (CKD-EPI) equation. Participants with estimated GFR between 50 - 60 mL\u002Fmin will require a 99mTc-TPA GFR test and only participants with non-obstructive pathology will be included in the study.\n    * \\*\\* Total bilirubin ≤ 2x ULN (except for participants with known Gilbert's Syndrome ≤ 3x ULN is permitted)\n* International Prostate Symptoms Score (IPSS) ≤ 15.\n* Medically fit for treatment and agreeable to follow-up.\n* Ability to understand and the willingness to sign a written informed consent.\n* Participants with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 14 weeks from receiving the last dose of Lu-PSMA-617. Participants must also not donate sperm for 14 weeks from receiving the last dose of Lu-PSMA-617.\n\nExclusion Criteria:\n\n* Clinical or radiographic evidence of distant metastatic disease (M1a above aortic bifurcation, M1b, or M1c) by any imaging. Participants are allowed to M1a nodal disease that is below the aortic bifurcation. Negative PSMA PET\u002FCT is an acceptable substitute to conventional staging.\n* Prostate gland size \\>90 cc measured by CT, ultrasound, or MRI\n* Prior head and neck radiation therapy.\n* Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy).\n* Prohibited within 30 days prior to administration to study treatment: spironolactone and other investigational drug therapies.\n* Prohibited 3 months before participant registration and during administration of study treatment: oral ketoconazole, , estrogens, and radiopharmaceuticals.\n* History of prior pelvic radiation therapy.\n* Enrollment concurrently in another investigational drug study within 6 months of registration.\n* History of another active malignancy within the previous 3 years except for adequately treated skin cancer or superficial bladder cancer.\n* History of prior myelodysplastic syndrome or acute leukemia.\n* History of or active Crohn's disease or ulcerative colitis.\n* Contraindication to or inability to tolerate PSMA\u002FPET.\n* Any condition that in the opinion of the investigator would preclude participation in this study.\n* Inability to adhere to radiation safety measures in hospital or at home\n* Prior treatment with radionuclide therapies, 177Lu-PSMA-617 or other\n* Reduced salivary gland function with baseline CTCAE Gr \\> 1 dry mouth will be excluded.","MALE","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer.\n\nParticipants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.",[28,29],"Malignant Neoplasm of Prostate","Locally Advanced Prostate Cancer",[31],"Prostate cancer","RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-26","ACTUAL",{"date":38,"type":36},"2025-05-13",{"date":40,"type":21},"2027-03-01",{"name":42,"class":43},"Angela Y. Jia, MD PhD","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100526150","phase-1-relugolix--enzalutamide-study-in-high-risk-prostate-cancer-100526150","NCT06130995","Relugolix + Enzalutamide Study in High-Risk Prostate Cancer","Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant\u002F Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)","Inclusion Criteria:\n\n1. Capable of giving signed informed consent;\n2. Patients must be ≥18 years of age at the time of signing the informed consent form.\n3. Men with a diagnosis of adenocarcinoma of the prostate pathologically proven diagnosis with the following:\n\n   • Locally advanced high-risk prostate defined as i. PSA \\>20 ng\u002FmL or ISUP grade 4\u002F5 (Gleason score \\>7) or cT2c or ii. Any PSA, any ISUP grade, cT3-4 or cN+ (locally advanced)\n4. Have normal organ and bone marrow function measured at the screening visit including\n\n   * Platelets ≥100 × 103\u002Fmicroliter (μL);\n   * Hemoglobin ≥ 10.0 grams\u002FdL;\n   * Leukocytes (WBC) ≥ 3 × 103\u002FμL;\n   * Absolute neutrophil count ≥1.5 × 103\u002FμL;\n   * Serum AST and ALT ≤2.5 × upper limit of normal (ULN);\n   * Total bilirubin ≤1.5 ×ULN (unless values are consistent with Gilbert's syndrome for which the total bilirubin must be \\\u003C 3x ULN);\n   * Serum creatinine ≤ 1.5 × ULN; OR Measured or calculated creatinine clearance ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n6. The participant has, in the opinion of the investigator, a life expectancy of at least 6 months.\n7. Male patients must be willing to use contraception during treatment and for 3 months after the last dose of study treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.\n\nExclusion Criteria:\n\n1. History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 6 months.\n2. Patients who are receiving any other investigational agents.\n3. Patients with distant metastatic cancer will be excluded from the study as intermittent hormonal therapy is not standard of care treatment for this population.\n4. Active secondary malignancies requiring treatment\n5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of study drugs\n6. Participants with uncontrolled intercurrent illness.\n7. Participant is unable to swallow pills.\n8. Not a candidate for surgical or radiation therapy",{"count":53,"type":21},46,[24],"The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse.\n\nThe main questions we want to answer in this study are:\n\n* Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer?\n* Does this combination treatment help patients live longer without their cancer getting worse?\n\nParticipants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.",[57,29],"Androgen Deprivation Therapy",[59,60,61,62],"dose limiting toxicity (DLTs)","pathologic complete response (pCR)","minimal residual disease (MRD)","radiation therapy (RT)","2026-03-03",{"date":65,"type":36},"2026-03-05",{"date":67,"type":36},"2024-12-26",{"date":69,"type":21},"2030-01",{"name":71,"class":43},"University of Oklahoma",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100619340","addition-of-focal-boost-to-primary-radiotherapy-for-prostate-cancer-in-12-or-20-fractions-100619340","NCT07343349","Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions: A Large DAPROCA Randomised Trial.","DAPROCA10","Inclusion Criteria:\n\n* Patients with biopsy verified PCa with no distant metastases with either\n* Intermediate- or high-risk PCa, defined as at least one of the following risk criteria:\n\n  * Clinical stage cT2c-T3b (UICC TNM 8th edition)\n  * Imaging stage, T3a or T3b\n  * ≥ Gleason score 4+3, (ISUP Grade groups 3,4 or 5)\n  * Regional lymph node metastases N1\n* Age \\> 18\n* WHO score 0-1\n* Intraprostatic lesion visible on MRI\n* Suitable for focal boost\n* Ability to give written informed consent and willingness to return for follow-up\n\nExclusion Criteria:\n\n* WHO performance status ≥ 2\n* If, for any patient related reason, an MRI cannot be performed\n* T4\n* International prostate symptom score (IPSS) ≧ 20\n* If fiducial markers cannot be inserted\n* TURP within 3 months from start of treatment\n* Previous pelvic irradiation\n* If the patient is judged by the physician to be unable to adhere to trial activities\n* History of chronic inflammatory bowel disease (CIBD)",{"count":81,"type":21},1016,[83],"NA","Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and globally. The aim is to reduce later cancer spreading, need of hormone treatments and prostate cancer death.\n\nDAPROCA 10 tests two possible improvements:\n\nIf a higher dose (boost) to intra-prostatic tumor lesions improves cure rates. If the radiotherapy can be given with 12 treatment fractions instead of 20 without increased side-effects.\n\nIn this randomised trial half the participants get a boost and the other half don't. Half the patients get 12 treatments, the other half 20.\n\nTo answer these questions we must include1016 participants. The trial is feasible because the technological advances in imaging and radiotherapy enables us to define the tumors in the prostate and to deliver the boost to the tumors with high precision, without increased dose to the surrounding organs.",[86,87,29,88],"Prostate Cancer Patients Undergoing External Radiation and Seed Implantation","High Risk Localised Prostate Carcinoma","Unfavourable Intermediate Risk Prostate Cancer",[31,90,91,92],"Radiotherapy","Hypofractionation","Boost","2026-01-19",{"date":95,"type":36},"2026-01-21",{"date":97,"type":36},"2025-12-15",{"date":99,"type":21},"2040-10-30",{"name":101,"class":43},"Rigshospitalet, Denmark",3,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100591244","improved-robotic-assisted-radical-prostatectomy-for-locally-advanced-prostate-cancer-bladder-suspension-and-preliminary-outcomes-100591244","NCT06977906","Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes","Inclusion Criteria:\n\n1. prostate biopsy and clinical confirmation of high-risk prostate cancer (PSA \\> 20 ng\u002FmL, Gleason score ≥ 8, or cT stage ≥ T2c) followed by robotic-assisted radical prostatectomy\n2. multiparametric MRI (mpMRI) with a 3.0 T scanner for prostate or pelvic scans performed within 30 days before the operation at our center\n3. Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1\n4. Complete clinical and prostate biopsy pathological data.\n5. General health is good, with no infections, autoimmune diseases, hematologic disorders, or other malignancies.\n\nExclusion Criteria:\n\n1. Presence of surgical contraindications.\n2. refusal of enhanced mpMRI imaging.",{"count":110,"type":21},300,[83],"This study is a prospective, single-center clinical trial. It aims to establish an improved robotic-assisted radical prostatectomy for treating locally advanced prostate cancer. The technique evaluates the impact of preserving the anterior peritoneum of the bladder on postoperative bladder descent and urinary control recovery. A retrospective analysis compares this modified approach with traditional anterior approach surgery, assessing differences in oncological outcomes, early functional recovery, and postoperative complication rates. The goal is to provide new theoretical foundations and technical support for the prevention and treatment of postoperative urinary incontinence.",[114,29,115],"Robotic-Assisted Radical Prostatectomy","Bladder Suspension",[114,29,115],"2025-05-12",{"date":119,"type":36},"2025-05-18",{"date":121,"type":36},"2024-01-01",{"date":123,"type":21},"2027-01-01",{"name":125,"class":43},"First Affiliated Hospital of Fujian Medical University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":44},"100545833","phase-2-genomic-biomarker-guided-neoadjuvant-therapy-for-prostate-cancer-segno-100545833","NCT06387056","Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)","An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)","SEGNO","Inclusion Criteria:\n\n* Males ≥ 18 years of age;\n* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrolment in the trial to document their willingness to participate;\n* Imaging examination (defined by multiparametric magnetic resonance imaging, radionuclide bone scan and PSMA PET\u002FCT (prostate-specific membrane antigen positron emission tomography\u002Fcomputed tomography) confirmed locally advanced (identified as cT3b to cT4, N0 to N1, M0) and oligometastatic (identified as no visceral metastasis and ≤5 bone metastases) prostate cancer. Participants are considered tolerable to radical prostatectomy (RP) and pelvic lymph node dissection (PLND) after neoadjuvant therapy (NT). Participants must consent to RP and PLND after NT when defined as tolerable for RP and PLND at registration and prior to enrolment in the trial;\n* Histologically confirmed adenocarcinoma of the prostate without pathologic evidence of small cell and neuroendocrine differentiation at the time of initial diagnosis;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and a life expectancy of ≥ 3 years;\n* Participants must have adequate end-organ function to tolerate NT and subsequent RP+PLND and all laboratory tests must be performed within 4 weeks prior to registration into master protocol. Including the following indicators: hemoglobin (Hb) ≥85g\u002FL; White blood cell count (WBC) ≥3.0×109 \u002FL; Platelet (PLT) ≥ 75×109 \u002FL; Liver function: Total bilirubin (TBIL) ≤1.5×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5× upper limit of normal value (ULN); Albumin (ALB) ≥25g\u002FL; Renal function: glomerular filtration rate (GFR) ≥ 60ml\u002Fmin;\n* Participants must consent to genetic testing at registration and prior to enrolment in the trial;\n* No prior systemic or localized treatment for prostate cancer. Up to 28 days of LHRHa, non-steroidal anti-androgen (NSAA) and novel hormone therapy (rezvilutamide) are allowable prior to treatment;\n* Participants must have the ability to swallow oral medication and follow the study procedure;\n* Participants must consent to use reliable contraceptive methods (such as condoms) and not to donate sperm throughout the study period and for 3 months after the last NT administration;\n* Participants must have no contraindications to any of the relevant drug treatments in the study.\n\nExclusion Criteria:\n\n* Participants with a history of hypersensitivity to any of the relevant drugs involved in this study;\n* Participants received more than 28 days of LHRHa, non-steroidal anti-androgen (NSAA) and novel hormone therapy (rezvilutamide) prior to registration, or enrolled in any other clinical studies for therapeutic purposes within 28 days prior to enrollment, or received any approved anticancer therapy within 28 days prior to enrollment;\n* Participants received local treatments of primary or metastatic lesions prior to enrollment;\n* Participants received bilateral orchiectomy prior to enrollment;\n* Hypogonadism or severe androgen deficiency as defined by screening serum testosterone more than 50 ng\u002FdL below the normal range for the institution;\n* Participants with a history of brain metastases or epilepsy;\n* Participants with severe cardiovascular disease, including: myocardial infarction or thrombosis in the previous 6 months; known unstable angina; history of documented congestive heart failure (New York Heart Association functional classification III-IV; QT interval \\> 480 ms; uncontrolled hypertension defined as resting systolic blood pressure \\> 170 mmHg or diastolic blood pressure \\> 105 mmHg;\n* Participants with clinically significant digestive tract abnormalities that may affect the process of drug intake, transport, or absorption (e.g. inability to swallow, chronic diarrhea, intestinal obstruction, etc., or total gastrectomy);\n* Participants with other clinically significant co-morbidities evaluated by the investigator, including uncontrolled lung disease, active central nervous system disease, active or uncontrolled bacterial, viral, or fungal infections requiring systemic treatment, or any other disease that may make the participant inappropriate for enrollment or RT + PLND after NT;\n* Participants with other known active cancers requiring treatment at the time of entry to the study, or had other malignancies within 5 years prior to enrollment;\n* Participants received surgeries other than diagnostic prostate biopsy within 4 weeks before enrollment;\n* Participants with active or known human immunodeficiency virus (HIV) with detectable viral load; active hepatitis B, defined as positive HBV DNA viral load or as defined by relevant guidelines; hepatitis C virus (HCV), except for those have been treated and have an undetectable viral load;\n* Participants with a history of non-compliance to medical regimen or inappropriate for the study, attributed to not meeting the principle of optimal benefit treatment.",{"count":135,"type":21},40,[25],"To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.",[29,139],"Oligometastatic Prostate Cancer","2024-04-24",{"date":142,"type":36},"2024-04-26",{"date":144,"type":36},"2024-04-01",{"date":146,"type":21},"2029-04-01",{"name":148,"class":43},"The First Affiliated Hospital of Xiamen University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":44},"100470525","phase-2-neoadjuvant-intense-endocrine-therapy-for-high-risk-and-locally-advanced-prostate-cancer-100470525","NCT05406999","Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","A Prospective, Multi-arm, Multi-center Clinical Trial on Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","Inclusion Criteria:\n\n1. All patients must have been histologically diagnosed of prostate cancer and must be eligible for radical prostatectomy.\n2. All patients must undergo thorough tumor staging and meet one of the following criteria: a) multi-parameter MRI or PSMA PET\u002FCT shows clinical staging of primary tumor ≥ T3; b) Gleason score of primary tumor ≥ 8; c)prostate specific antigen(PSA) ≥20 ng\u002Fml; d) Imaging evaluation shows regional lymph node metastases (N1).\n3. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1.\n4. Patients must have adequate hematologic function, hepatic function, renal function and cardiac function.\n5. Patients must participate voluntarily and sign an informed consent form(ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must bewilling to obey the prohibitions and restrictions specified in the research protocol.\n6. Fertile patients must be willing to use highly effective contraception during the study period and within 120 days of the last dose of treatment.\n\nExclusion Criteria:\n\n1. Patients with neuroendocrine, small cell, or sarcoma-like pathologic features are not eligible.\n2. Patients with low-risk or medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: a) multiparameter MRI or PSMA PET \u002F CT shows clinical staging of primary tumor \\\u003C T3; b) Gleason score of primary tumor \\\u003C 8; c) prostate specific antigen (PSA) \\\u003C20 ng\u002Fml.\n3. Patients with clinical or radiological evidence of extra-regional lymph node metastases or bone metastases or visceral metastases (any M1) are not eligible.\n4. Patients who have previously received androgen deprivation therapy (medical or surgical) or focal treatment, radiotherapy, chemotherapy for prostate cancer are not eligible.\n5. Patients with severe or uncontrolled concurrent infections are not eligible.\n6. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration.\n7. Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.\n8. Patients must not have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.\n9. Patients with mental illness, mental disability or inability to give informed consent are not eligible.","80 Years",{"count":158,"type":21},900,[25],"This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.",[162,163,29,164],"Neoadjuvant Therapy","High Risk Prostate Cancer","Intense Endocrine Therapy","2022-08-12",{"date":167,"type":36},"2022-08-16",{"date":169,"type":36},"2020-02-01",{"date":171,"type":21},"2030-06-30",{"name":173,"class":43},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"]